Corcept Therapeutics (CORT) Interest Expenses (2010 - 2017)

Corcept Therapeutics has disclosed Interest Expenses across 8 years of filings, most recently posting $98000.0 for Q2 2017.

• Interest Expenses for Q2 2017 came in at $98000.0, down 81.54% year-over-year; the trailing twelve-month figure through Mar 2018 was $98000.0 (down 94.07% YoY), and the FY2016 annual result was $2.0 million, down 31.23% from the prior year.
• Interest Expenses came in at $98000.0 for Q2 2017 at Corcept Therapeutics, down from $225000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.2 million in Q3 2013 to a low of $98000.0 in Q2 2017.
• The 5-year median for Interest Expenses is $785000.0 (2015), against an average of $755833.3.
• Across the five-year window, Interest Expenses surged 22720.0% in 2013 and slumped 81.54% in 2017, its largest moves.
• Corcept Therapeutics' Interest Expenses stood at $1.1 million in 2013, then slipped by 25.23% to $818000.0 in 2014, then slipped by 15.4% to $692000.0 in 2015, then tumbled by 40.75% to $410000.0 in 2016, then plunged by 76.1% to $98000.0 in 2017.
• The last three Interest Expenses figures came in at $98000.0 (Q2 2017), $225000.0 (Q1 2017), and $410000.0 (Q4 2016), per Business Quant data.